Anacetrapib

Drug Profile

Anacetrapib

Alternative Names: MK-0859

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; University of Oxford
  • Class Antihyperlipidaemics; Oxazolidinones; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for anacetrapib in USA (Merck Annual report 2016)
  • 12 Nov 2016 Pharmacodynamics data from a phase I trial in Hypercholesterolaemia presented at the 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 10 Oct 2016 Cambridge University Hospitals NHS Foundation Trust and British Heart Foundation Cambridge Centre of Excellence plan the observational REVEAL-Vasc sub-study for Atherosclerosis (Adjunctive treatment) in United Kingdom (PO) (NCT02931188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top